Two years Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study

Autor:	Pugliese, D, Privitera, G, Rogai, F, Variola, A, Viola, A, Laterza, L, Privitera, Ac, Allocca, M, Bossa, F, Cappello, M, Daperno, M, Lorenzon, G, Mazzuoli, S, Principi, M, Sablich, R, Moser, L, Ferronato, A, Traini, S, Tapete, G, Bodini, G, Di Girolamo, M, Grossi, L, Mocci, G, Ricci, C, Saibeni, S, Festa, S, Spagnuolo, R, Cortelezzi, Cc, Mocciaro, F, Rizzello, F, Armuzzi, A, Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	remission naïve persistence Golimumab ulcerative colitis
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=od______3662::b9eeeeb39d91f01c2fb4abb13495e94b http://hdl.handle.net/11379/556555 Zobrazit plný text záznamu